Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors

NCT00436254 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00436254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00436254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2001
Completion date
April 1, 2025
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, stage iii ovarian epithelial cancer, stage iii ovarian germ cell tumor, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor